Xu Wei

AnHeart Therapeutics (Hangzhou) Co., Ltd. engages in the development of pharmaceutical products. Its offers neurotrophic tyrosine receptor kinase and c-ros oncogene 1 dual-target inhibitors for cancer treatment. The company was founded by Jun Yuan Wang, Bing Yan and Li Hua Zheng on November 27, 2018 and is headquartered in Hangzhou, China.

AnHeart Therapeutics (Hangzhou) Co., Ltd. engages in the development of pharmaceutical products. Its offers neurotrophic tyrosine receptor kinase and c-ros oncogene 1 dual-target inhibitors for cancer treatment. The company was founded by Jun Yuan Wang, Bing Yan and Li Hua Zheng on November 27, 2018 and is headquartered in Hangzhou, China.

AnHeart Therapeutics (Hangzhou) Co., Ltd. engages in the development of pharmaceutical products. Its offers neurotrophic tyrosine receptor kinase and c-ros oncogene 1 dual-target inhibitors for cancer treatment. The company was founded by Jun Yuan Wang, Bing Yan and Li Hua Zheng on November 27, 2018 and is headquartered in Hangzhou, China.

AnHeart Therapeutics (Hangzhou) Co., Ltd. engages in the development of pharmaceutical products. Its offers neurotrophic tyrosine receptor kinase and c-ros oncogene 1 dual-target inhibitors for cancer treatment. The company was founded by Jun Yuan Wang, Bing Yan and Li Hua Zheng on November 27, 2018 and is headquartered in Hangzhou, China.

AnHeart Therapeutics (Hangzhou) Co., Ltd. engages in the development of pharmaceutical products. Its offers neurotrophic tyrosine receptor kinase and c-ros oncogene 1 dual-target inhibitors for cancer treatment. The company was founded by Jun Yuan Wang, Bing Yan and Li Hua Zheng on November 27, 2018 and is headquartered in Hangzhou, China.